COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03171064
Recruitment Status : Recruiting
First Posted : May 31, 2017
Last Update Posted : March 25, 2020
Department of Dermatology, Heidelberg University Hospital
Information provided by (Responsible Party):
Joachim Wiskemann, University Hospital Heidelberg

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : March 1, 2021